Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Julphar
Argus Health
US Army
Merck
Chinese Patent Office
Cantor Fitzgerald
Express Scripts
Cerilliant

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXYMORPHONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Oxymorphone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00225797 Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain Completed Endo Pharmaceuticals Phase 3 The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.
NCT00226395 Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain Completed Endo Pharmaceuticals Phase 3 The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
NCT00226421 Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain Completed Endo Pharmaceuticals Phase 3 The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
NCT00260260 OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain Completed Odense University Hospital Phase 4 Patients undergoing surgery (thyroidectomy and hysterectomy) will postoperatively receive oxycodone intravenously (IV) as pain management with morphine as an escape medicine, if there is insufficient pain relief with oxycodone. Patients' pain and side effects will be registered and after 24 hours they will answer a questionnaire. All included patients will be genotyped accordingly to CYP2D6 and relevant single nucleotide polymorphisms (SNPs), and measures of plasma levels of oxycodone will be performed.
NCT00271973 OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models Completed Odense University Hospital Phase 4 Thirty-two healthy volunteers will be submitted to experimental pain and on the 2 study days receive Oxycodone 20 mg po vs. placebo. Half of the volunteers will be poor metabolizers according to CYP2D6 genotype and half will be extensive metabolizers (EM) and have an enzyme with normal function. The study hypothesis is that PM will experience less pain relief than EM.
NCT00580294 A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation) Completed Endo Pharmaceuticals N/A The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients. This study will examine if the switching from one pain medication to another can be done over a 24 hour period. Oxymorphone, the drug being studied, is an FDA approved drug for treatment of severe pain.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Oxymorphone Hydrochloride

Condition Name

Condition Name for Oxymorphone Hydrochloride
Intervention Trials
Pain 9
Chronic Pain 6
Postoperative Pain 2
Post-operative Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Oxymorphone Hydrochloride
Intervention Trials
Chronic Pain 7
Pain, Postoperative 6
Acute Pain 2
Neuralgia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Oxymorphone Hydrochloride

Trials by Country

Trials by Country for Oxymorphone Hydrochloride
Location Trials
United States 97
Denmark 2
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Oxymorphone Hydrochloride
Location Trials
Texas 9
North Carolina 7
Pennsylvania 7
Florida 6
Colorado 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Oxymorphone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Oxymorphone Hydrochloride
Clinical Trial Phase Trials
Phase 4 7
Phase 3 13
Phase 1 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Oxymorphone Hydrochloride
Clinical Trial Phase Trials
Completed 17
Not yet recruiting 4
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Oxymorphone Hydrochloride

Sponsor Name

Sponsor Name for Oxymorphone Hydrochloride
Sponsor Trials
Endo Pharmaceuticals 17
Odense University Hospital 2
Sandoz 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Oxymorphone Hydrochloride
Sponsor Trials
Industry 22
Other 11
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Argus Health
Deloitte
Medtronic
Queensland Health
Julphar
Merck
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.